relapsed or refractory adult T-cell leukemia-lymphoma

February 19, 2019

Poteligeo Proves Safe, Effective for ATL Patients in Clinical Setting

News

Poteligeo (mogamulizumab), an approved treatment for relapsed or refractory adult T-cell leukemia-lymphoma (ATL) patients in Japan, is also safe and effective in a real-world clinical setting, a postmarketing surveillance study found. ... Read more

June 13, 2016June 13, 2016

Mogamulizumab More Effective Than Chemotherapy for Adult T-Cell Leukemia-Lymphoma, Study Finds

News

Results from a Phase 2 clinical trial demonstrate that the drug mogamulizumab promotes better response rates than standard chemotherapy in patients with a rare form of cancer, called relapsed of refractory adult T-cell leukemia-lymphoma ... Read more